Home > > > > > Report Detail

Autoimmune Partnering Terms and Agreements

Publisher Name :
Date: 01-Mar-2015
No. of pages: 1000
Inquire Before Buying

The Autoimmune Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies.


  • Trends in autoimmune partnering deals

  • Average deal terms for headline, upfront and royalty by stage of development

  • Autoimmune partnering agreement structure

  • Autoimmune partnering contract documents

  • Top autoimmune deals by value

  • Most active autoimmune dealmakers


The Autoimmune Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter autoimmune partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors autoimmune  technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains a comprehensive listing of all autoimmune partnering deals announced since 2010 including financial terms where available, including over 700 links to online deal records of actual autoimmune partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in autoimmune  dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading autoimmune deals since 2010. Deals are listed by headline value, signed by big pharma, big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of autoimmune deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of autoimmune deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all oncology partnering deals signed and announced since 2010 with a contract attached. The chapter is organized by autoimmune  deal type, stage of development and technology type focus. Each deal title links via Weblink to an online version of the deal record with the contract document.

Chapter 7 provides a comprehensive directory of all autoimmune partnering deals signed and announced since 2010. The chapter is organized by specific autoimmune therapy focus, including inflammatory bowel disease, psoriasis, endometriosis, lupus, type 1 diabetes and much more . Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all autoimmune partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in autoimmune partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of autoimmune technologies and products.

Report scope

Autoimmune Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to autoimmune trends and structure of deals entered into by leading companies worldwide.

Autoimmune Partnering Terms and Agreements includes:


  • Trends in autoimmune dealmaking in the biopharma industry since 2010

  • Analysis of autoimmune deal structure

  • Access to headline, upfront, milestone and royalty data

  • Case studies of real-life oncology deals

  • Access to over 700 autoimmune deals since 2010 and contract documents where available

  • The leading autoimmune deals by value since 2010

  • Most active autoimmune dealmakers since 2010

  • The leading autoimmune partnering resources


In Autoimmune Partnering Terms and Agreements, the available contracts are listed by:

  • Headline value

  • Upfront payment value

  • Royalty rate value

  • Stage of development at signing

  • Deal component type

  • Technology type

  • Specific autoimmune therapy indication


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Autoimmune Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 700 autoimmune deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise autoimmune rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?


Benefits

Autoimmune Partnering Terms and Agreements provides the reader with the following key benefits:


  • In-depth understanding of autoimmune deal trends since 2010

  • Access to headline, upfront, milestone and royalty data

  • Comprehensive access to over 700 actual autoimmune deals entered into by the world’s biopharma companies

  • Detailed access to actual autoimmune contracts enter into by biopharma industries

  • Insight into the terms included in a autoimmune agreement, together with real world clause examples

  • Understand the key deal terms companies have agreed in previous deals

  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Autoimmune Partnering Terms and Agreements

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in autoimmune dealmaking
2.1. Introduction
2.2. Autoimmune partnering over the years
2.3. Big pharma autoimmune dealmaking activity
2.4. Big biotech autoimmune dealmaking activity
2.5. Most active in autoimmune partnering
2.6. Autoimmune partnering by deal type
2.7. Autoimmune partnering by industry sector
2.8. Autoimmune partnering by stage of development
2.9. Autoimmune partnering by technology type
2.10. Autoimmune partnering by oncology indication
2.11. Average deal terms for autoimmune
2.11.1 Autoimmune headline values
2.11.2 Autoimmune upfront payments
2.11.3 Autoimmune milestone payments
2.11.4 Autoimmune royalty rates

Chapter 3 – Leading autoimmune deals
3.1. Introduction
3.2. Top autoimmune deals by value

Chapter 4 – Big pharma autoimmune deals
4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma autoimmune partnering company profiles

Chapter 5 – Big biotech autoimmune deals
5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech autoimmune partnering company profiles

Chapter 6 – Autoimmune partnering contracts directory
6.1. Introduction
6.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
Warranty
6.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
6.4. By technology type
Adjuvant
Analysis
Antibodies
Assays
Biological compounds
Biomarkers
Biomaterials
Biosimilars/Bio-betters
Blood products
Cell culture
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Enviromental
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Implant
Industrial chemicals
In vitro models
Microarray
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Pharmacogenomics
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Vaccines

Chapter 7 – Autoimmune dealmaking by indication
7.1. Introduction
7.2. Deals by therapeutic indication
Autoimmune
CNS: Multiple sclerosis
CNS: Restless leg syndrome
Dermatology: Eczema
Hair disorders: Alopecia
Dermatology: Psoriasis
Gastrointestinal: Celiac disease
Gastrointestinal: Inflammatory bowel disease
Gastrointestinal: Inflammatory bowel disease > Crohn’s disease
Gastrointestinal: Inflammatory bowel disease > Ulcerative colitis
Genitourinary: Renal infections > Glomerulonephritis
Gynecology: Endometriosis
Hematology: Immune thrombocytopenic purpura
Hematology: Neutropenia
Immunology: Graft versus host disease
Immunology: Scleroderma
Immunology: Systemic lupus erythematosus
Metabolic: Addison’s disease
Metabolic: Diabetes > Type 1
Musculoskeletal: Ankylosing spondylitis
Musculoskeletal: Juvenile arthritis
Musculoskeletal: Psoriatic arthritis
Musculoskeletal: Rheumatoid arthritis
Ophthalmics: Uveitis
Psychiatry: Sleep disorders > Narcolepsy
Respiratory: Idiopathic pulmonary fibrosis
Respiratory: Sarcoidosis
Sensory organs: Hearing disorders > Meniere's disease
Other autoimmune diseases

Chapter 8 – Partnering resource center
8.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Upgrades to subscription access products
Order Form – Therapy Reports

Appendices
Appendix 1: Directory of autoimmune deals by Company A-Z 2010-2015
Appendix 2: Directory of autoimmune deals by stage of development 2010-2015
Appendix 3: Directory of autoimmune deals by deal type 2010-2015
Appendix 4: Directory of autoimmune deals by technology type 2010-2015

List of Figures

Figure 1: Autoimmune partnering since 2010
Figure 2: Big pharma – top 50 – autoimmune deals 2010 to 2015
Figure 3: Big pharma autoimmune deal frequency – 2010 to 2015
Figure 4: Big biotech – top 50 – autoimmune deals 2010 to 2015
Figure 5: Big biotech autoimmune deal frequency – 2010 to 2015
Figure 6: Active autoimmune dealmaking activity– 2010 to 2015
Figure 7: Autoimmune partnering by deal type since 2010
Figure 8: Autoimmune partnering by industry sector since 2010
Figure 9: Autoimmune partnering by stage of development since 2010
Figure 10: Autoimmune partnering by technology type since 2010
Figure 11: Autoimmune partnering by oncology target since 2010
Figure 12: Autoimmune deals with a headline value
Figure 13: Autoimmune deal headline value distribution, US$million – discovery stage
Figure 14: Autoimmune deal headline value distribution, US$million – preclinical stage
Figure 15: Autoimmune deal headline value distribution, US$million – phase I stage
Figure 16: Autoimmune deal headline value distribution, US$million – phase II stage
Figure 17: Autoimmune deal headline value distribution, US$million – phase III stage
Figure 18: Autoimmune deal headline value distribution, US$million – regulatory stage
Figure 19: Autoimmune deal headline value distribution, US$million – marketed stage
Figure 20: Summary median headline value by stage of development, 2009-2014
Figure 21 Autoimmune deals with upfront payment values
Figure 22: Autoimmune deal upfront payment distribution, US$million – discovery stage
Figure 23: Autoimmune deal upfront payment distribution, US$million – preclinical stage
Figure 24: Autoimmune deal upfront payment distribution, US$million – phase I stage
Figure 25: Autoimmune deal upfront payment distribution, US$million – phase II stage
Figure 26: Autoimmune deal upfront payment distribution, US$million – phase III stage
Figure 27: Autoimmune deal upfront payment distribution, US$million – regulatory stage
Figure 28: Autoimmune deal upfront payment distribution, US$million – marketed stage
Figure 29: Summary median upfront payments by stage of development, 2010-2015
Figure 30: Autoimmune deals with milestone payments
Figure 31: Autoimmune deal milestone distribution, US$million – discovery stage
Figure 32: Autoimmune deal milestone distribution, US$million – preclinical stage
Figure 33: Autoimmune deal milestone distribution, US$million – phase I stage
Figure 34: Autoimmune deal milestone distribution, US$million – phase II stage
Figure 35: Autoimmune deal milestone distribution, US$million – phase III stage
Figure 36: Autoimmune deal milestone distribution, US$million – regulatory stage
Figure 37: Autoimmune deal milestone distribution, US$million – marketed stage
Figure 38: autoimmune deals with royalty rates, %
Figure 39: Autoimmune deal royalty rate distribution, US$million – discovery stage
Figure 40: Autoimmune deal royalty rate distribution, US$million – preclinical stage
Figure 41: Autoimmune deal royalty rate distribution, US$million – phase I stage
Figure 42: Autoimmune deal royalty rate distribution, US$million – phase II stage
Figure 43: Autoimmune deal royalty rate distribution, US$million – phase III stage
Figure 44: Autoimmune deal royalty rate distribution, US$million – regulatory stage
Figure 45: Summary median royalty rate by stage of development, 2010-2015
Figure 46: Top autoimmune deals by value since 2010

  • Global Systemic Lupus Erythematosus (Sle) Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Nov-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Systemic Lupus Erythematosus (Sle) Drugs market: According to our latest research, the global Systemic Lupus Erythematosus (Sle) Drugs market looks promising in the next 5 years. As of 2022, the global Systemic Lupus Erythematosus (Sle) Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents......
  • Autoimmune Drugs Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 78
    This study focuses on China's Autoimmune Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. Th......
  • Autoimmune Drugs Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 71
    This study focuses on China's Autoimmune Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of......
  • Autoimmune Drugs Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 201
    China's demand for Autoimmune Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, indu......
  • Autoimmune Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 450
    Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of autoimmune deals from 2016 to 2023. The report includes coverage of the following autoimmune diseases: Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Infla......
  • Global Autoimmune Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 29-Aug-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Autoimmune Drugs market: According to our latest research, the global Autoimmune Drugs market looks promising in the next 5 years. As of 2022, the global Autoimmune Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Autoimmune Drugs market......
  • Global Autoimmune Drugs Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 92
    Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by chronic inflammatory processes that activate the innate immune system and the production of antibodies that destroy host tissues. These inflammatory processes can be caused by genetic or environmental ......
  • Global Systemic Lupus Erythematosus (SLE) Drugs Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 75
    SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of ......
  • Global Systemic Lupus Erythematosus (Sle) Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 11-Jul-2023        Price: US 3260 Onwards        Pages: 130
    The Systemic Lupus Erythematosus (Sle) Drugs market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Systemic Lupus Erythematosus (Sle) Drugs industry, and breaks down according to the type, application, and consumption area of Systemic Lupus Erythematosus (Sle) Drugs. The report also introduces players in the industry from the per......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs